Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
Nichi-Iko Pharmaceutical is now in the final phase of deliberations with Kyowa Pharmaceutical Industry on their potential collaboration in generic manufacturing, the company’s president Shingo Iwamoto revealed to Jiho in an interview on January 28. The two generic makers aim…
To read the full story
Related Article
- And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
- Mochida and Itochu to Each Take 20% Stake in And Pharma
September 24, 2025
- And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
- Nippon Chemiphar Signs On to Meiji-Daito Consortium as Talks Accelerate
July 22, 2025
- JWP-Led Holdings Firm Launched for Nichi-Iko, Kyowa, and Teva Takeda
July 15, 2025
- Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group
December 9, 2024
- Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
- Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
- Kyowa Pharma Hit by Biz Suspension over Manufacturing Flaws, Record Fabrications
March 29, 2022
- Unison Capital Shows Rising Presence with Kyowa Deal, PE Fund Potential Catalyst for Industry Shakeup?
November 22, 2019
BUSINESS
- Fycompa Generics Head for Summer Launch as Key Patent Expires
June 23, 2026
- ASKA’s Relugolix Combo Hits Primary Goal in Japan PIII Fibroid Study
June 23, 2026
- Rege Nephro Raises 1.22 Billion Yen to Advance ADPKD Drug, iPSC Kidney Program
June 23, 2026
- Japan OTC Drug Market Falls for Third Straight Month in May: Intage
June 23, 2026
- Lilly Japan Names Karla Alcazar as New President
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…